These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9435853)

  • 1. Clinical perspectives of bispecific antibodies in cancer.
    de Gast GC; van de Winkel JG; Bast BE
    Cancer Immunol Immunother; 1997; 45(3-4):121-3. PubMed ID: 9435853
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor vaccines and active specific immunotherapy].
    Schirrmacher V
    Internist (Berl); 1997 Nov; 38(11):1050-4. PubMed ID: 9453953
    [No Abstract]   [Full Text] [Related]  

  • 3. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bi-specific antibodies in cancer therapy.
    Wang H; Liu Y; Wei L; Guo Y
    Adv Exp Med Biol; 2000; 465():369-80. PubMed ID: 10810641
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies in cancer therapy.
    Weiner LM
    Cancer J; 2000 May; 6 Suppl 3():S265-71. PubMed ID: 10874497
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor-antigen-binding bispecific antibodies for cancer treatment.
    Weidle UH; Kontermann RE; Brinkmann U
    Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.
    Kiefer JD; Neri D
    Immunol Rev; 2016 Mar; 270(1):178-92. PubMed ID: 26864112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies and diabodies for cancer immunotherapy.
    Elsässer-Beile U; Bühler P
    Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of bispecific antibodies: Clinical applications and challenges.
    Lim SM; Pyo KH; Soo RA; Cho BC
    Cancer Treat Rev; 2021 Sep; 99():102240. PubMed ID: 34119803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies poised to deliver wave of cancer therapies.
    Sheridan C
    Nat Biotechnol; 2021 Mar; 39(3):251-254. PubMed ID: 33692520
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bispecific antibodies in hematology and oncology].
    Repp R; Valerius T; Bargou R
    Internist (Berl); 2001 Jun; 42(6):854-9. PubMed ID: 11449632
    [No Abstract]   [Full Text] [Related]  

  • 18. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
    Ferrini S; Sforzini S; Canevari S
    Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.